Volume 14, Issue 2 (Volume 14, No 2 2023)                   jdc 2023, 14(2): 71-81 | Back to browse issues page

XML Persian Abstract Print


1- Center for Research and Training in Skin Diseases and Leprosy,Tehran University of Medical Sciences, Tehran, Iran
2- Department of Research and Development, Pharmed Salamat Sina Co, Tehran, Iran
3- Center for Research and Training in Skin Diseases and Leprosy,Tehran University of Medical Sciences, Tehran, Iran , aniseh_samadi@yahoo.com
Abstract:   (1411 Views)

Background and Aim: In order to overcome the local side effects of the conventional treatments for atopic dermatitis, a new attitude regarding alternative treatments would be needed, which herbal medicines are promising approachs in this case.
 

Methods: It was a 4-week, before-after clinical study, conducted on 20 participants (16 women and 4 men) aged 39.95±11.04 years. The severity scoring of atopic dermatitis was determined based on total & local SCORAD. skin biophisical parameters including TEWL ,skin hydration, pH, temperature, sebum and skin erythema were also measured after 2 and 4 weeks application of the study product. Participants’ satisfaction as well as tolerability of the product were assessed by monitoring the adverse effects.
 

Results: A significant improvement was detected in LOCAL and TOTAL SCORAD at weeks 2 and 4 (P<0.01). The intensity of burning and pruritus also showed a significant decrease at weeks 2 and 4 (P<0.01). A significant increase in the skin hydration was shown at weeks 2 and 4 after treatment (P<0.01). 84.1% and 78.9% of participants described their skin lesions as "improved" or "much improved", 2 and 4 weeks after treatment respectively.
 

Conclusion: The test cream containing oats and chamomile extract is considered a safe and effective product for improving mild to moderate lesions of atopic dermatitis.

Full-Text [PDF 1325 kb]   (580 Downloads)    
Type of Study: Research | Subject: General

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.